Health‐related quality of life among pediatric patients with acute lymphoblastic leukemia: An exploratory cross‐sectional study

Abstract

AbstractBackgroundImproved survival rates broadened the pediatric oncology focus to include health‐related quality of life (HRQoL). This cross‐sectional study aimed to examine HRQoL by treatment phase and disease risk level in pediatric patients with B‐cell acute lymphoblastic leukemia (B‐ALL), including those in early survivorship.ProcedureA subset of data from a larger prospective cohort study was analyzed. Data were collected from 73 patients (73 parent reports and 28 self‐reports). Parent proxy and self‐report PROMIS measures assessed HRQoL across treatment phases (early intensive, maintenance, and off treatment) and disease risk groups (standard vs high). Analyses assessed the relationship between parent proxy and patient self‐reports and the differences in HRQoL among treatment phases and risk groups.ResultsParent proxy reports generally indicated worse fatigue, pain interference, and mobility compared with patient self‐reports. Self‐reports in the early intensive treatment group suggested worse depressive symptoms, fatigue, mobility, and upper extremity function compared with those in later phases. Parent proxy reports showed worse fatigue and depressive symptoms in early intensive treatment group relative to those in later phases. Patient self‐reports in the maintenance group demonstrated the best peer relationships scores. Parent proxy reports in the high‐risk group reported significantly higher depressive symptoms and fatigue compared with the standard‐risk group.ConclusionsDifferences in HRQoL suggest targets for further assessment and intervention. The early treatment and immediate post‐survivorship periods may represent particularly critical time points. Longitudinal studies with larger and diverse samples should further explore HRQoL trajectories in this population.